Coenzyme Q10 Bioproduction Engineering Service

Coenzyme Q10 (CoQ10, Ubiquinone), an essential component of the mitochondrial electron transport chain, is a highly valuable supplement and pharmaceutical used for cardiovascular and neurological health. Production faces challenges: low microbial fermentation yield due to complex, energy-intensive biosynthesis and tight metabolic regulation; and insufficient purity in chemical synthesis , which often yields cis-isomers and difficult-to-separate byproducts. This necessitates a high-purity, high-yield bioproduction route.

CD Biosynsis offers a synthetic biology service focused on establishing an efficient CoQ10 production platform using Saccharomyces cerevisiae (Baker’s Yeast). Our core strategy involves modification of the isoprene pathway in Saccharomyces cerevisiae (specifically the MVA pathway, which provides the deca-isoprenyl side chain) to increase the supply of the precursor decaprenyl pyrophosphate (DPP) . This is coupled with the overexpression of key enzymes for CoQ10 synthesis (such as the CoQ gene cluster enzymes and HHMG-CoA reductase) to boost the conversion rate of precursors into the final product. This integrated approach aims to deliver a high-titer, pure, and cost-effective naturally produced all-trans-CoQ10 product.

Pain Points

Developing a competitive CoQ10 bioproduction route faces these critical limitations:

• Low Microbial Fermentation Yield: The native CoQ10 pathway is long (requiring over 10 genes) and highly regulated, meaning the host cell prioritizes sterol synthesis (e.g., ergosterol) over CoQ10 production, limiting yield.
• Insufficient Purity in Chemical Synthesis: Chemical routes often lead to a mixture of the active all-trans form and biologically inactive cis-isomers , requiring costly and difficult purification steps to meet quality standards.
• Precursor Competition: Key intermediate FPP is rapidly consumed by the sterol pathway (Squalene synthase), creating a metabolic bottleneck that limits CoQ10 production.
• Hydrophobicity and Extraction: CoQ10 is highly hydrophobic and stored within the cell's membrane, making efficient extraction and recovery difficult and expensive.

A successful solution must significantly enhance precursor supply and efficiently divert metabolic flux into the CoQ10 pathway.

Solutions

CD Biosynsis utilizes advanced metabolic engineering to optimize CoQ10 production in S. cerevisiae :

Modification of Isoprene Pathway in S. cerevisiae

           

We upregulate the key rate-limiting enzyme HMG-CoA reductase (tHMG1) and block competing pathways (e.g., sterol synthesis by knocking out ERG9) to maximize DPP precursor supply.

Overexpression of Key Enzymes for CoQ10 Synthesis

We use high-copy plasmids or genomic integration to overexpress CoQ10 specific enzymes (COQ gene cluster) to boost the conversion of DPP and PHB into CoQ10.

Decaprenyl Pyrophosphate Synthase Engineering

We modify or replace the native isoprene transferase (CoQ specific polyprenyl diphosphate synthase) to ensure the precise C50 side chain length (10 isoprenyl units) required for CoQ10.

Cofactor and Redox Optimization

We engineer the host to improve NADPH supply (essential for the upstream MVA pathway) and manage the redox state of the cell for optimal CoQ10 function and stability.

This systematic approach is focused on optimizing both the precursor supply and the final conversion pathway to maximize CoQ10 accumulation.

Advantages

Our CoQ10 engineering service is dedicated to pursuing the following production goals:

High All-trans Purity

Biosynthesis naturally produces the active all-trans isomer with high specificity, avoiding the low purity of chemical synthesis.

Significantly Increased Titer

Enhanced precursor flux and pathway boost overcome natural bottlenecks, leading to high industrial yields .

Cost-Effective Yeast Platform

Utilizing S. cerevisiae provides a robust, low-cost fermentation system with established scale-up protocols.

Sustainable Sourcing

Microbial fermentation uses renewable sugar feedstock , reducing dependence on complex petrochemical inputs.

Reduced Byproduct Formation

Targeted gene knockout prevents the co-formation of sterols, simplifying downstream purification .

We provide a specialized platform aimed at maximizing the quality and cost-effectiveness of CoQ10 biomanufacturing.

Process

Our CoQ10 strain engineering service follows a rigorous, multi-stage research workflow:

• Sterol Pathway Blockage: Knock out squalene synthase (ERG9) and other sterol synthesis genes to divert FPP from sterols toward CoQ10 synthesis.
• Upstream MVA Pathway Enhancement: Overexpress key rate-limiting enzymes (tHMG1) to increase the pool of isopentenyl diphosphate (IPP) precursors.
• CoQ10 Gene Cluster Optimization: Use multi-copy integration or high-expression promoters to overexpress COQ}3$ through COQ9 enzymes, maximizing conversion efficiency.
• Polyprenyl Synthase Tuning: Optimize the specific polyprenyl diphosphate synthase to ensure exclusive production of the C50 side chain (Decaprenyl diphosphate).
• Fermentation Performance Validation: Test the final engineered strain in fed-batch fermentation to assess CoQ10 titer, yield, and all-trans purity .
• Result Report Output: Compile a detailed Experimental Report including gene modification data, flux analysis, and fermentation metrics (yield, titer, and purity) , supporting commercial scale-up.

Technical communication is maintained throughout the process, focusing on timely feedback regarding yield and product purity.

Explore the potential for a high-yield, high-purity CoQ10 supply. CD Biosynsis provides customized strain engineering solutions:

• Detailed Metabolic Flux and Titer Analysis Report , demonstrating success in carbon redirection and titer increase.
• Consultation on cell lysis and organic solvent extraction methods optimized for high-efficiency CoQ10 recovery.
• Experimental reports include complete raw data on carbon yield (g CoQ}10/\text{g sugar) and all-trans purity , essential for regulatory and commercial use.